Does Dr. MADEEHA ABDUL GHAFFAR have financial conflicts of interest?

Dr. MADEEHA ABDUL GHAFFAR (MD) has received a total of $773 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $773 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MADEEHA ABDUL GHAFFAR?

According to CMS Open Payments data, Dr. MADEEHA ABDUL GHAFFAR received funding from BAYER HEALTHCARE PHARMACEUTICALS ($136), NOVARTIS PHARMACEUTICALS CORPORATION ($116), and MALLINCKRODT HOSPITAL PRODUCTS ($114).

Does Dr. MADEEHA ABDUL GHAFFAR receive research grants or speaking fees?

Dr. MADEEHA ABDUL GHAFFAR has received $773 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MADEEHA ABDUL GHAFFAR

MDReal-Time Hydrated

Specialty: Internal Medicine

Practice Location: ELKTON, MD 21921

NPI Number: 1194276063

LIFETIME INDUSTRY VALUE

$773

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABDUL GHAFFAR is a verified Internal Medicine practitioner based in ELKTON, MD.

Between 2021 and 2024, Dr. ABDUL GHAFFAR had an overall industry promotional and research financial footprint of $773 as recorded in the federal CMS Open Payments database.

$773 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDUL GHAFFAR's primary funding source is BAYER HEALTHCARE PHARMACEUTICALS, which accounts for $136 (representing 17.6% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

BAYER HEALTHCARE PHARMACEUTICALS

Rank 1

$136

17.6%

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 2

$116

15%

MALLINCKRODT HOSPITAL PRODUCTS

Rank 3

$114

14.8%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.